Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) has concluded an oversubscribed round raising EUR 8.4m bridge financing round. The capital will enable the startup to complete preclinical activities and prepare for entry into Phase I clinical trials.
Founded in 2012 by scientist Guido Grentzmann and a team of experienced scientists and life science entrepreneurs supported by leading nephrologists in Switzerland and Europe, Opterion Health AG is developing a novel peritoneal dialysis (PD) solution. Its mission is to revolutionise the dialysis market and foster home dialysis to improve quality of life for patients and their loved ones and strives to increase the survival rates of people who suffer from end-stage renal disease (ESRD). In 2015, a small number of renowned life science investors joined Opterion to support the company in achieving its mission.
Animal studies have shown the superiority of the Opterion PD solution over the “gold standard” of the current market leader. According to Grentzmann, «The PD market has not seen any significant innovation for over two decades. Hence, there is a high unmet medical need for a novel solution that not only offers better therapy outcomes but also has the potential for reduced side effects, improved quality of life and higher survival rates of dialysis patients».
«Over 45% of dialysis patients have diabetes, and an increasing number of patients no longer want to visit a clinic or a hospital for their therapy. This is especially true in times of pandemic, as we are currently experiencing. Therefore, our glucose-free PD solution is a much-needed innovation not only for the significant number of diabetic dialysis patients but also for dialysis patients who want to improve their quality of life by having their therapy at home,» he adds.
Today, the company announced the closing of an oversubscribed round with a limited number of professional private and institutional investors based in Switzerland and Germany. The capital will fund Opterion’s final preclinical activities to create a new standard in Peritoneal Dialysis (PD) and prepare for Phase I.
Andreas Schmidt, CFO of Opterion adds: “Thanks to the very successful completion of our financing round – which was oversubscribed by more than 40% – Opterion is now in the position of being very comfortably financed for the next two years. This allows us to execute our scientific as well as manufacturing plans and prepare for Phase I with full speed.”
Opterion joins the Basel life science ecosystem
In addition to closing the bridge round, Opterion also announced that it will relocate its offices to Muttenz (BL) to become part of the life science ecosystem in the Basel area.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines